Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer : report of a phase I/II dose-escalating study
Thomas, A. L., Cox, G., Sharma, R. A., Steward, W. P., Shields, F., Jeyapalan, K., Muller, S., & O'Byrne, Kenneth J. (2000) Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer : report of a phase I/II dose-escalating study. European Journal of Cancer, 36(18), pp. 2329-2334.
The aim of this phase I/II dose escalating study was to establish the maximum tolerated dose (MTD) of gemcitabine and paclitaxel given in combination in non-small cell lung cancer (NSCLC). 12 patients with stage IIIB and IV NSCLC received paclitaxel administered intravenously over 1 h followed by gemcitabine given over 30 min on days 1, 8 and 15 every 28 days. Pneumonitis was the principal side-effect observed with 4 patients affected. Of these, 1 experienced grade 3 toxicity after one cycle of treatment and the others had grade 2 toxicity. All 4 cases responded to prednisolone. No other significant toxicities were observed. Of the 8 evaluable patients, 3 had a partial response and 2 had minor responses. The study was discontinued due to this dose-limiting toxicity. The combination of paclitaxel and gemcitabine shows promising antitumour activity in NSCLC, however, this treatment schedule may predispose to pneumonitis. (C) 2000 Elsevier Science Ltd.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Gemcitabine, Non-small cell lung cancer, Paclitaxel, Pneumonitis, prednisolone, adult, aged, antineoplastic activity, article, cancer staging, cancer survival, clinical article, clinical trial, dose response, drug efficacy, female, human, lung non small cell cancer, male, phase 1 clinical trial, phase 2 clinical trial, pneumonia, priority journal, treatment outcome, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cohort Studies, Deoxycytidine, Dose-Response Relationship, Drug, Humans, Lung Neoplasms, Maximum Allowable Concentration, Middle Aged|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2000 Pergamon|
|Deposited On:||08 Jan 2014 00:37|
|Last Modified:||08 Jan 2014 00:39|
Repository Staff Only: item control page